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1. Introduction 
Met-enkephalin (Met-Ek) is the 6 l-65 fragment 
of /3-lipotropin with amino acid sequence Tyr’ - 
Gly’ -Gly3 -Phe4 -Met’. It is one of the endogenous 
ligands for morphine receptors in brain and smooth 
muscle. Recent semi-empirical conformational 
analysis of the molecule [1,2] showed its high 
conformational mobility. (It should be noted, how- 
ever, that in [l] the end groups of the molecule have 
been assumed to be uncharged, whilst in [2] a number 
of potentially stable structures has been omitted in 
the treatment owing to certain features of the calcula- 
tion pattern.) On the other hand, biological activity 
tests of Met-Ek analogs with restricted conformational 
freedom have shown that [D-Ala*] -Met-Ek possesses 
increased affinity for morphine receptors, this 
property being reduced for [D-Ala31 -Met-Ek [3] . A 
comparison of these data with known sets of stable 
conformations of these molecules ought to make it 
possible to discern the conformation (or set of con- 
formations) of the Met-Ek molecule which is 
characteristic for receptor binding. This would mean 
solving the important problem of structural and func- 
tional organization of the Met-Ek molecule. Such a 
‘biologically active’ set of conformations must con- 
tain stable structures, common for Met-Ek and 
[D-Ala*] -Met-Ek, excluding at the same time 
[D-Ala3]-Met-Ek structures (elements of such an 
approach can be found in [4] ). 
2. Methods and rest&s 
To approach the problem, a total semi-empirical 
conformational nalysis of Met-Ek, [D-Ala* ]-Met- 
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Ek and [D-Ala31 -Met-Ek zwitterionic forms was 
done. (Since the conformational mobility of the two 
latter molecules i  restricted, only structures belong- 
ing to the set of stable Met-Ek conformations were 
subjected to examination.) The basic methods and 
calculation patterns have been described [5,6], 
including the calculation of conformational energy 
of model fragment Ala-Gly-Gly-Ala-Ala and 
tripeptides Tyr-Gly-Gly, Gly-Gly-Phe and 
Gly-Phe-Met for the initial steps of the calculations. 
The final stage of the calculations consisted in 
examining the conformational lability of Tyr’ side- 
chain for the most stable conformations of the pep- 
tide backbone of the molecule, since in most cases 
the conformations of the tyrosine side-chain are 
practically not correlated with the conformations of 
phenylahmine and methionine side-chains. 
Results of our calculations show that the set of 
stable backbone structures of Met-Ek is considerably 
restricted by electrostatic nteraction of the ionogenic 
end groups, leading to formation of quasicyclic molec- 
ular structures (cf. table 1). In addition, there is also 
a restriction in mobility of the Phe4 backbone, limit- 
ing to the B and R regions only (in terms of local 
minima of the dipeptide unit potential maps, B corre- 
sponding to values cp --140°, J/-140’, R to cpw-60°, 
J/--60”, L to (p-60’, 9-60’ and H to (p-80’, 
J/--SO” [ 191) as well as enhanced conformational 
lability of dipeptides Tyr-Gly and Gly-Gly, as com- 
pared with dipeptides Gly-Phe and Phe-Met, the 
mobihties of Tyr’ , Phe4 and Met’ side-chains 
remaining approximately equal (with certain limita- 
tions for all rotamers with x1 ---60”). 
These features of calculated Met-Ek structures are 
in agreement with NMR data, thus confirming the 
validity of our approach. Indeed, close spacing of the 
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Table 1 
Stable conformations of Met-Ek, [D-Ala’ ] -Met-Ek and [D-Ala’] -Met-Ek 
Conformational energy CJ-Umm (kcal/mol) of Tyr’ rotamers with different x1 valuesa 
- 60” - 180” --60” 
RRRBL 
BBRRB 
BHLBB 
RBHRB 
BLLBL 
RHRBL 
RRBBL 
RLRRB 
BHHRB 
RLLRB 
BBLRB 
RHRRB 
BHRRB 
RHBRB 
BHRBL 
BLBRB 
BLLBB 
BLRRB 
BBLBL 
BHRBB 
RRHRB 
BLHBL 
_ - 
0.9 - 
4.3 5.0 
- - 
3.2 4.5 
_ _ 
- - 
- - 
- - 
- - 
- - 
5.4 - 
6.0 _ 
_ _ 
_ - 
- _ 
- 4.7 - - 0.0 - _ 
2.9 - - - - - - 
1.1 2.6 3.9 1.5 - - - 
- 3.2 - 1.8 2.7 - 0.7 
0.3 5.7 2.6 3.9 - _ 
3.5 1.1 3.6 3.4 - - 0.0 
- - - _ - 3.4 - 
3.4 1.4 - - - - - 
- 3.7 4.4 - 4.5 - - 
- - - - 3.7 - 4.6 
- 3.8 - 0.4 4.2 - 3.3 
- - - 3.8 - 5.2 - 
- 5.1 5.6 3.9 4.0 - 5.5 
_ _ - - 4.2 0.0 - 
- 5.3 3.5 5.6 4.9 5.0 4.8 
5.1 _ 5.7 - - - 
_ - - 5.1 - _ 3.6 
_ _ - - 5.4 _ - 
- - - _ - 5.6 4.4 
- 5.8 1.5 - - - - 
5.9 - 3.5 _ _ _ _ 
- _ - - - _ - 
a Side-chain rotamers of other residues: xi - 180”) x1 - 90’ for Phe, x1 - -8O”, xa, x, ,- 180” for Met in 
all cases with exception of BLLBB, BLHBB, and BHRBB, where xz - 80’ for Met; the dihedral angle 
values are in accordance with [ 191. Energies above 6 kcal/mol are not included in the table 
N- and C-termini is shown in [7-91 ; high mobility of 
the dipeptide Tyr-Gly features in [lo] ; the vicinal 
constant JNHCOLH values according to [7,9,1 l-131 
are in good agreement with the majority of structures 
listed in table 1; finally, in many of the stable struc- 
tures the amide protons of Gly3 and Met5 are situated 
on the inside part of the &turn formed by the back- 
bone which, apparently, accounts for the lowering 
of the da/dTvahre for these protons, as observed in 
[7,9,10-12,141. 
3. Discussion 
The comparatively high rigidity of the Tyr’ side- 
chain (x1 -180”) is one of the principal structural 
characteristic features of the [D-Ala2 ]-Met-Ek. Since 
the rigid thyramine moiety of morphine is of special 
functional significance [ 151 , it stands to reason that 
the very fact of ‘fured’ distance between the OH and 
NH’, groups accounts to some extent for the increased 
binding capacity of [D-Ala* ] -Met-Ek towards 
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morphine receptor (the respective distances being: 
7.5-8.0 A in [D-Ala2]-Met-Ek, 5.6-8.0 A in Met-Ek 
and 7.0 A in morphine, with NH(CHa)+ in the latter 
instead of NH;. This circumstance enables us to sug- 
gest hat the adequate spacing of the Tyr’ side-chain 
and of the NH’, group of the Met-Ek molecule is 
‘selected’ by the receptor according to the induced-fit 
principle. The role of the remaining amino acid 
residues of the molecule in structure formation is, 
apparently, confined to maintaining such structures 
in which the Tyr’ side-chain islocated on the ‘bend’ 
of the peptide backbone and points ‘outward’. The 
existence of morphine-mimetic a tivity of some 
/3-lipotropin fragments starting with Ty#‘l, as well as 
decrease in activity of Met-Ek after elimination of 
the C-terminus [ 161 also speaks in favour of the 
above suggestion. Moreover, the loss of activity caused 
by Phe4 + Tyr4 or Met’ + Gly’ replacement [ 161 
also points towards participation of the hydrophobic 
C-terminal moieties of the molecule in receptor 
binding and, accordingly, towards their location close 
to the ‘main’ Tyr’ residue. 
The data listed in table 1 enable us also to select 
the set of ‘biologically active’ Met-Ek conformations: 
it includes RLRRB, BHHRB, RHBRB, BLHBB and 
BHRBB (BLHBB differing from BHRBB only by a 
180” turn of the Gly’ -Gly3 peptide bond plane). 
Only one of these structures, however, namely 
BHRBB, is found to be stable, according to confor- 
mational energy calculations for a Met-Ek molecule 
with uncharged end groups (only optimal rotamers of 
the Tyr’ side-chain were considered; calculation 
results are in good agreement with those from [l] ). 
Comparison with the high activity of the [D-Ala21 - 
Met-Ek-NH2 speaks in favour of selecting one single 
‘biologically active’ Met-Ek structure (selection 
scheme presented in fig. 1). The structure suggests a 
p-1 turn with participation of residues l-4; more 
stable Met-Ek structures would contain a p-1 turn 
with residues 2-5. 
The concept of ‘biologically active’ conformation 
of Met-Ek, namely BHRBB, easily explains the loss of 
receptor affinity of [GAla’] -Leu-Ek and [GAla2, 
GAla -Leu-Ek [ 171, since the H-type conformation 
is sterically inconsistent for L-type ammo acids (it 
explains also loss of affinity of the [D-Phe4] -Met-Ek 
[3] , the B-type conformation being inconsistent in 
this case). ‘Biologically active’ conformation is also 
[D-AL+MET-EK 
1 
-ALG]-MET-EK 
-NH? 
Fig.1. Selection scheme and view of ‘biologically active’ 
Met-Ek conformation. 
feasible in the case of the highly active [D-Met’, 
Pro’]-Ek analog [181, since, as can be seen from 
fig. 1, the D-Met2 side-chain iscapable of occupying 
the same place on the receptor surface, as the Met’ 
side-chain. On the other hand, loss of affinity of 
[D-Leu’]-Met-Ek, [D-Phe’] -Met-Ek [3] and 
[LAla3]-Leu-Ek [17] cannot be explained in terms 
of structural considerations only. It appears that an 
increase in hydrophobicity of the solvent-facing part 
of the molecule (cf. Ag.1) slackens its binding with 
the receptor. 
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